Biopharma Insights - Thought Leadership from Marketers | Paid Program
Viral contamination is an inherent risk during the manufacture of therapeutic products such as antibodies, vaccines, viral vectors, and plasma derivates.
David Cetlin, Biopharma Insights Contributor, Senior Director of R&D at Cygnus Technologies
Advertisement
David Cetlin is Senior Director of R&D at Cygnus Technologies. He can be contacted at david.cetlin@cygnustechnologies.com.
Articles by David Cetlin, Biopharma Insights Contributor, Senior Director of R&D at Cygnus Technologies
Advertisement
Latest Updated Articles
- Predicting Viral Clearance at Your Benchtop
July 27th 2020
Advertisement
Advertisement
Trending on BioPharm International
1
AstraZeneca Acquires Omniose, Adding Bioconjugate Vaccine Platform
2
The BioPharm Brief: FDA Designations for a Bispecific CAR-T, a BLA for Friedreich’s Ataxia, and Phase 2b MASH Data for Efinopegdutide
3
Updates on Simtra BioPharma Solutions’ Bloomington Capacity Expansions
4
Efinopegdutide Meets Primary Endpoint in Phase 2b MASH Trial
5